Clinical Trial Update: BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting Betaferon/Betaseron efficacy outcomes at a new dose for relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Betaferon (interferon beta-1b)
• Betaseron (Interferon beta-1b)

Snippet

Sponsor: Bayer | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED | Results posted: 2009-08-17